ArticleLupus science & medicine2026
Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic lupus erythematosus (SLE) is an autoimmune disorder characterised by multisystem involvement, frequently including cardiovascular manifestations. Interleukin 2 (IL-2), a key cytokine in immune regulation, plays a pivotal role in maintaining tolerance by promoting regulatory T cell function. The relationship between serum IL-2 levels and specific SLE features remains incompletely defined. The aim of our study was to investigate the associations between serum IL-2 concentrations and disease activity, inflammatory markers, autoantibody profiles as well as cardiovascular and metabolic parameters in a well-characterised cohort of patients with SLE.
methodsIn this cross-sectional study, 235 patients with SLE were recruited and characterised, including assessment of autoantibody profiles, disease activity indices (SLE Disease Activity Index-2000 (SLEDAI-2K)), Damage Index and remission status. Cardiovascular characteristics were evaluated, encompassing lipid profiles, insulin resistance indices and carotid ultrasound parameters such as plaque presence, intima-media thickness and arterial stiffness. Serum IL-2 concentrations were quantified using an ultrasensitive technique, the Single Molecule Array (Simoa). Multivariable linear regression was conducted to examine the associations between circulating IL-2 levels and clinical as well as cardiovascular manifestations of SLE.
resultsIn multivariable analyses, serum IL-2 levels showed significant positive associations with inflammatory markers including C reactive protein and IL-6. Disease activity, assessed by SLEDAI-2K, was positively correlated with IL-2 levels. Positive and significant associations were also noted, after adjustment for covariates, between IL-2 and specific autoantibodies, including anti-DNA, anti-Sjögren's syndrome antigen A (SSA), anti-Sjögren's syndrome antigen B (SSB), anti-Smith (Sm) and antiribosome. Regarding cardiovascular disease factors, triglycerides were positively associated with IL-2 whereas high-density lipoprotein-cholesterol exhibited an inverse relationship.
conclusionSignificant correlations exist between serum IL-2 levels and markers of inflammation, lipid profile, disease activity and specific autoantibody profiles in patients with SLE. These findings underscore the pivotal role of IL-2 in SLE immunopathogenesis, reflecting its intricate involvement in modulating both inflammatory responses and metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.